Author Linked-In Account

linkedin.com/in/dr-karolyn-infanta-david-10b15261

Biosketch

My name is Karolyn Infanta David, and I am a registered PhD student at SASTRA Deemed University. After earning my M.Tech. in Medical Nanotechnology (2021–2022), I decided to pursue a PhD to deepen my expertise in targeted drug delivery systems. I am fortunate to conduct my doctoral research under the guidance of Dr K. Uma Maheswari, Associate Dean of the School of Chemical & Biotechnology. Throughout my academic journey, I have gained valuable international experience and practical skills. Notably, I participated in the Japan–Asia Youth Exchange Programme in Science (Sakura Exchange Program) at Tokyo City University, Japan. This transformative opportunity expanded my scientific horizons and introduced me to global research cultures. Additionally, I have developed strong technical skills in operating advanced research facilities at SASTRA, including high-resolution Micro-CT imaging and microarray platforms, as well as other sophisticated analytical techniques essential for research. The broad knowledge, international outlook, and practical expertise I am acquiring during my PhD form the foundation for my long-term career goals.

Date of Award

24-6-2026

Document Type

Thesis

School

School of Chemical & Biotechnology

Programme

Ph.D.-Doctoral of Philosophy

First Advisor

Prof.Uma Maheswari Krishnan

Keywords

Multifunctional theranostic system, Pancreatic cancer, 3D spheroids, Gold-capped iron oxide Nanoparticles, Chitosan nanoparticles, Gemcitabine

Abstract

Cancer remains one of the leading causes of mortality worldwide, with pancreatic cancer exhibiting an exceptionally high mortality rate due to late diagnosis, aggressive disease progression, and the development of drug resistance. The present study aimed to develop multifunctional chitosan nanoparticles co-encapsulating gemcitabine, a first-line chemotherapeutic agent for pancreatic cancer, and hybrid iron oxide–gold nanoparticles (Fe@Au), which function as dual-modal contrast agents for magnetic resonance imaging (MRI) and computed tomography (CT). The developed nanoparticles were characterized for their physicochemical properties and drug-release kinetics using spectroscopic, thermal, and microscopic techniques. Additionally, a three-dimensional (3D) pancreatic cancer spheroid model was optimized using Matrigel® to mimic the tumour microenvironment and drug-resistant characteristics of pancreatic cancer.

The therapeutic efficacy of the developed nanoformulation was evaluated using 10-day-old pancreatic cancer spheroids. The co-encapsulated nanoparticles demonstrated enhanced cellular internalization and increased sensitization to gemcitabine in 3D cancer cultures. While a single dose was ineffective in the 3D spheroid model compared with conventional 2D cultures, repeated administration demonstrated improved therapeutic efficacy, effectively overcoming drug resistance. Furthermore, phantom agar assays conducted under cellular and cell-free conditions confirmed the potential of the nanoparticles to provide appreciable contrast in both MRI and CT imaging. The incorporation of the Fe@Au multimodal imaging agent also imparted stimuli-responsive properties, facilitating accelerated drug release through temperature elevation upon exposure to an alternating magnetic field.

An in vivo pancreatic cancer xenograft model was established using immunocompromised BALB/c mice to investigate the therapeutic and imaging potential of the nanoformulation. Following administration, the nanoparticles were successfully visualized using both MRI and CT imaging. In vivo MRI observations indicated predominantly hepatobiliary elimination, while tumour accumulation was further confirmed through Prussian blue staining following the 28-day experimental period. Therapeutic evaluation revealed that the combination of the nanoformulation and magnetic stimulation produced the greatest reduction in tumour volume compared with free gemcitabine, hyperthermia alone, and drug-loaded nanoparticles without magnetic stimulation.

Molecular investigations further demonstrated the downregulation of the anti-apoptotic protein Bcl-2 and the upregulation of the pro-apoptotic protein Bid and tumour suppressor protein p21, indicating the involvement of apoptotic pathways and suppression of tumour progression. Overall, the findings demonstrate the potential of multifunctional chitosan nanoparticles incorporating gemcitabine and Fe@Au as a promising theranostic platform for pancreatic cancer management by integrating chemotherapy, multimodal imaging, and magnetic field-responsive drug release. This approach may offer a promising strategy for improving therapeutic outcomes and addressing drug resistance in pancreatic cancer.

Share

COinS
 

Graphical Abstract